The BioPharm Brief: Gene Editing, Myeloma, Neuroregeneration

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today’s update highlights advances across cardiovascular disease, oncology, and neurodegenerative research, with new clinical and preclinical data pointing toward how next-generation therapies may reshape treatment landscapes in the years ahead.

First, Eli Lilly reported encouraging Phase 1 results for VERVE-102, an investigational in vivo gene-editing therapy targeting PCSK9 to reduce LDL cholesterol. According to the company, the therapy demonstrated durable LDL reductions after a single dose, reinforcing growing interest in one-time gene-editing approaches for cardiovascular disease management. Researchers also highlighted improvements in delivery technology designed to support safer and more targeted editing.

Meanwhile, the multiple myeloma treatment landscape continues evolving rapidly as late-stage CAR-T and bispecific antibody programs intensify competition across the market. Developers are racing to differentiate therapies based on efficacy, safety, manufacturing scalability, and outpatient administration potential. The pipeline reflects continued momentum toward personalized and immune-based approaches for heavily pretreated patients, while also raising questions around access, production capacity, and long-term positioning in an increasingly crowded field.

And in neurodegenerative disease research, preclinical findings for TFG-001 showed early signals of reinnervation in Parkinson’s disease models. Investigators reported evidence suggesting the therapy may help restore neural connectivity and functional recovery. While the program remains in preclinical development, the data adds to broader industry efforts exploring regenerative medicine strategies for neurological disorders where treatment options remain limited.

Taken together, these developments underscore how gene editing, cell therapy, and regenerative medicine continue driving innovation across multiple therapeutic categories.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

• Eli Lilly’s VERVE-102 demonstrated durable LDL cholesterol reduction in Phase 1 testing after a single dose.
• Late-stage CAR-T and bispecific therapies are reshaping the competitive landscape in multiple myeloma treatment.
• TFG-001 generated early preclinical evidence supporting neural reinnervation potential in Parkinson’s disease models.